Market data provided for informational purposes only. Not financial advice. Read disclaimers.
Market data provided for informational purposes only. Not financial advice. Read disclaimers.
AbbVie is a biopharmaceutical company that emerged from Abbott Laboratories in 2013. The company is navigating the Humira biosimilar cliff — Humira was the best-selling drug in history at peak sales of $21B — while growing its immunology successors Skyrizi and Rinvoq. AbbVie also operates in aesthetics (Botox, via Allergan acquisition) and neuroscience.
AbbVie's investment thesis is the Skyrizi + Rinvoq ramp replacing Humira erosion. Combined peak sales for the two drugs are projected at $27B+. The Allergan aesthetics portfolio (Botox, Juvederm) provides diversification. Revenue growth inflection timing is the key catalyst.